Literature DB >> 27018758

Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of Physicians.

Hilary Daniel.   

Abstract

This American College of Physicians position paper, initiated and written by its Health and Public Policy Committee and approved by the Board of Regents on 16 February 2016, reports policy recommendations from the American College of Physicians to address the escalating costs of prescription drugs in the United States. Prescription drugs play an important part in treating and preventing disease. However, the United States often pays more for some prescription drugs than other developed countries, and the high price and increasing costs associated with prescription medication is a major concern for patients, physicians, and payers. Pharmaceutical companies have considerable flexibility in how they price drugs, and the costs that payers and patients see are dependent on how payers are able to negotiate discounts or rebates. Beyond setting list prices are issues of regulatory approval, patents and intellectual property, assessment of value and cost-effectiveness, and health plan drug benefits. These issues are linked, and comprehensive efforts will be needed to affect how drugs are priced in the United States.

Entities:  

Year:  2016        PMID: 27018758     DOI: 10.7326/M15-2768

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  7 in total

1.  Cost Avoidance Utilizing a Batching Process for Isoproterenol.

Authors:  Douglas A Bloomstein; Michael Serra; Sunanda Baviskar; Stephen L Winters
Journal:  P T       Date:  2016-09

2.  Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.

Authors:  Natalie McCormick; Zachary S Wallace; Chana A Sacks; John Hsu; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2020-01-06       Impact factor: 10.995

Review 3.  Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA.

Authors:  Daniel M Hartung
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

4.  Patterns and predictors of physician adoption of new cardiovascular drugs.

Authors:  Timothy S Anderson; Wei-Hsuan Lo-Ciganic; Walid F Gellad; Rouxin Zhang; Haiden A Huskamp; Niteesh K Choudhry; Chung-Chou H Chang; Seth Richards-Shubik; Hasan Guclu; Bobby Jones; Julie M Donohue
Journal:  Healthc (Amst)       Date:  2017-10-21

5.  Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake.

Authors:  Narcyz Ghinea; Miles Little; Wendy Lipworth
Journal:  J Bioeth Inq       Date:  2017-07-18       Impact factor: 1.352

Review 6.  Bending Versus Transforming the Drug Cost Curve: A Matter of Political Will.

Authors:  Ajay Major; Blase N Polite
Journal:  Cancer J       Date:  2020 Jul/Aug       Impact factor: 2.074

7.  What is in your wallet? A cluster randomized trial of the effects of showing comparative patient out-of-pocket costs on primary care prescribing for uncomplicated hypertension.

Authors:  Robyn Tamblyn; Nancy Winslade; Christina J Qian; Teresa Moraga; Allen Huang
Journal:  Implement Sci       Date:  2018-01-10       Impact factor: 7.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.